Skip to search formSkip to main contentSkip to account menu

HIF-2alpha Inhibitor PT2385

Known as: PT2385 
An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
558 Background: The transcription factor hypoxia-inducible factor (HIF)-2α has been established as an oncogenic driver in clear… 
2018
2018
Faculty Opinions recommendation of Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell…
  • C. Jimenez
  • Faculty Opinions – Post-Publication Peer Review…
  • 2018
  • Corpus ID: 91496593
2018
2018
HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC.
The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC. 
2017
2017
Targeting HIF 2 in Clear Cell Renal Cell Carcinoma
Inactivation of the von Hippel–Lindau tumor-suppressor protein (pVHL) is the signature “truncal” event in clear cell renal cell… 
2017
2017
NAFLD: HIF2α: a new therapeutic target for NAFLD
  • Iain Dickson
  • Nature reviews: Gastroenterology & hepatology
  • 2017
  • Corpus ID: 33454357
axis promotes NAFLD. To test this hypothesis, HFD-fed mice with hepatic steatosis were treated with PT2385, a HIF2α-specific… 
2017
2017
In situ expression of hypoxia inducible factor 2-alpha in gliomas.
e13534Background: Hypoxia, a driver of malignancy, is fundamental to glioblastoma (GBM). Of the hypoxia inducible transcription… 
2016
2016
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
2506Background: Inactivation of the von Hippel Lindau (VHL) tumor suppressor occurs in the majority of clear cell renal cell… 
2015
2015
Abstract DDT01-01: PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
Hypoxia-inducible factors (HIFs), including HIF-1α and HIF-2α, are transcription factors that mediate cellular response to… 
2004
2004
Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma.
AIM To investigate the expression of hypoxia-inducible factor (HIF)-2alpha/endothelial PAS domain protein1 (EPAS1) in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)